2023 ASCO

Breast Cancer ASCO 2023 Highlights with Dr. Stephanie Graff

Discussing Breast Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies:

– NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients

– SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients

– X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer

Algorithms Journal of Breast Cancer

HR+ Breast Cancer Management with Dr. Margaret Gatti-Mays

Discussing the management of Hormone Receptor Positive Breast Cancer with Dr. Margaret Gatti-Mays, Section Chief of the Breast Medical Oncology at the Ohio State University Comprehensive Cancer Center, The James Cancer Hospital & Solove Research Institute. In our discussion with Dr. Gatti-Mays we cover the treatment algorithm of the hormone receptor-positive disease following the FDA expanding the adjuvant abemaciclib approval where one doesn’t need Ki-67 levels anymore, and new agents recently approved by the FDA – elacestrant, TDXD and sacituzumab providing more treatment options for our patients.

Algorithms Journal of Breast Cancer

HR+ Invasive Lobular Carcinoma Management with Dr. Jason Mouabbi

Discussing the management of Invasive Lobular Carcinoma with Dr. Jason Mouabbi from the MD Anderson Cancer Center. We see different histologies in hormone receptor-positive breast cancer patients – we will focus on invasive lobular carcinoma in this video. Are these patients different than one with invasive ductal carcinoma? How does the prognosis differs?

Algorithms Journal of Breast Cancer

HER2+ Breast Cancer Algorithm Discussion with Dr. Paolo Tarantino

Discussing the management using an algorithm of HER 2 Neu Positive Breast Cancer – with Dr. Paolo Tarantino, European Institute of Oncology, Clinical Research Fellow at the Dana-Farber Cancer institute.

2022 ESMO

Breast ESMO 2022 Highlights with Dr. Maryam Lustberg

Discussing Breast Cancer ESMO 2022 Highlights – Practice changing studies with Dr. Maryam Lustberg, Director of Center of Breast Cancer, Chief of Breast Medical Oncology, Associate Professor of Internal Medicine at Yale Cancer Center – Yale School of Medicine.

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology